ArticleCancer reports (Hoboken, N.J.)2026
Decoding the Oncogenic Role of USP22 Through Pan-Cancer Genomic and Epigenetic Analysis.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulatory roles of five key USP family deubiquitinases in cancer: from mechanisms to targeted therapy advances.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundUbiquitin-specific protease 22, an important catalytic component of the human SAGA (Spt-Ada-GcN5 Acetyltransferase) complex, regulates the deubiquitination and methylation of histones, which in turn influences gene expression. Its overexpression alters gene regulation, transcription, cancer progression, and therapy resistance. Its role is increasingly being noticed in cancers.
aimsTo conducted a pan-cancer analysis across multiple malignancies, as it allows for a comprehensive assessment of USP22 expression, regulation, and clinical impact.
methodsThe Human Protein Atlas, UALCAN, and Timer 2.0 were used to examine USP22 expression at the gene and protein levels in 33 TCGA cancer types. Furthermore, various tools have been employed to study genetic changes, overall survival (OS), disease-free survival (DFS), DNA methylation profiles, and immune associations. Gene correlation and protein-protein interaction were examined.
resultsUSP22 expression level was observed to be significantly higher in 13 distinct cancer types among the 33 TCGA cancer types. Along with the pathological stages of the TCGA sample, it showed overexpression in the histological subtypes, TP53 mutant stages, and tumor grade in numerous cancers compared to the control. According to the study, elevated USP22 expression was linked to a worse chance of survival and a lower OS rate in several types of cancer. High expression of USP22 is linked to a poor immunosuppressive microenvironment, and the CpG-aggregated methylation analysis shows that the gene is significantly hypomethylated in tumor samples, which is highly associated with its known upregulation in cancer.
conclusionUSP22 may have potential relevance in cancer, and the pathways associated with it could offer possible targets for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.